Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma—rationale for targeting ARID1A deficiency

Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma

(2021) Shumei Song et al.   GUT

A CRISPR/Cas9-engineered ARID1A-deficient human gastric cancer organoid model reveals essential and non-essential modes of oncogenic transformation

(2021) Yuan-Hung Lo et al.   Cancer Discovery

YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition

(2020) Jaffer A Ajani et al.   GUT

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma

(2020) Shumei Song et al.   Molecular Oncology

Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer

(2020) Leo Yamada et al.   Gastric Cancer

Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors

(2020) Lulu Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Arid1a is essential for intestinal stem cells through Sox9 regulation

(2019) Yukiko Hiramatsu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response

(2019) Ruiping Wang et al.   GUT

PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression

(2019) Shumei Song et al.   MOLECULAR CANCER RESEARCH

ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice

(2018) Yoshito Kimura et al.   GASTROENTEROLOGY

Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer

(2018) Yi Ping Zhu et al.   HUMAN PATHOLOGY

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

Game of TOR — The Target of Rapamycin Rules Four Kingdoms

(2017) Brendan D. Manning   NEW ENGLAND JOURNAL OF MEDICINE

AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells

(2017) Dakeun Lee et al.   OncoTargets and Therapy

Gastric adenocarcinoma

(2017) Jaffer A. Ajani et al.   Nature Reviews Disease Primers

Global chemotherapy development for gastric cancer

(2016) Kazuto Harada et al.   Gastric Cancer

The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice

(2016) Nithya Kartha et al.   GENETICS

Various ARID1A expression patterns and their clinical significance in gastric cancers

(2016) Young-Bae Kim et al.   HUMAN PATHOLOGY

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

(2016) Jaffer A. Ajani et al.   Journal of the National Comprehensive Cancer Network

Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1

(2016) Qian Zhang et al.   Oncotarget

The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice

(2016) Nithya Kartha et al.   GENETICS

Global Cancer Incidence and Mortality Rates and Trends--An Update

(2015) L. A. Torre et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Potential therapeutic targets inARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis

(2015) Claudio Luchini et al.   Oncotarget

Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties

(2014) S. Song et al.   CANCER RESEARCH

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

(2014) Miwako Kakiuchi et al.   NATURE GENETICS

Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer

(2014) Kai Wang et al.   NATURE GENETICS

Loss of TGF-  Adaptor  2SP Activates Notch Signaling and SOX9 Expression in Esophageal Adenocarcinoma

(2013) S. Song et al.   CANCER RESEARCH

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections

(2013) Maria Lina Tornesello et al.   GENOMICS

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

(2012) Yan Wang et al.   CANCER CELL

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer

(2012) Dan-dan Wang et al.   PLoS One

Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling

(2012) Shumei Song et al.   PLoS One

Management of advanced gastric cancer

(2012) Timothy J Price et al.   Expert Review of Gastroenterology & Hepatology

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

(2011) Kai Wang et al.   NATURE GENETICS

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma

(2010) Daichi Maeda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers

(2010) Bryan T. Hennessy et al.   Clinical Proteomics

The SWI/SNF complex and cancer

(2009) D Reisman et al.   ONCOGENE